Vermillion Delisted from Nasdaq; Will Trade on Pink Sheets

Sep 25, 2008

NEW YORK (GenomeWeb News) – Vermillion said today that it has been delisted from the Nasdaq Capital Market as of this morning due to noncompliance with Nasdaq’s minimum requirements.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Genomic Vision 1H 2017 Revenues Up 15 Percent
Coimbra Genomics Supporting Portugese Clinical Exome Sequencing Initiative
UPDATE: CRISPR Stakeholders Seek Reversal of Patent Interference Proceeding Decision
Thermo Fisher Scientific Q2 Revenues Up 10 Percent; Firm Increases 2017 Guidance Again
Adaptive Biotechnologies, NCI Collaborate on Immunosequencing Biomarker Discovery
Gastric Cancer Subtypes Found to Have Different Prognoses

The Scan

Cloud Ready

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

The New Yeast

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

The Science and Policy Connection

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

This Week in Cell

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.

Main menu